Compositions comprising receptor-associated protein (RAP) variants specific for LRP2 and uses thereof

• US 8,877,714 B2
• Filed: 06/14/2006
• Issued: 11/04/2014
• Est. Priority Date: 06/14/2005
• Status: Expired due to Fees

• Current Assignee: Horizon Orphan, LLC (Amgen Inc.)
• Original Assignee: Biomarin Pharmaceutical Incorporated (Amgen Inc.)
• Inventors: Starr, Christopher M., Zankel, Todd C.
• Primary Examiner(s): BALLARD, KIMBERLY
• Application Number:
  US11/576,506
• Publication Number:
  US 20090269346A1
• Time in Patent Office: 3,065 Days
• Field of Search: None
• US Class Current: 514/21.2
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 14/705 Receptors; Cell surface antigens; Cell surface determinants tumour specific antigens C07K14/4748

Abstract

The present invention relates generally to receptor-selective variants of the low-density lipoprotein receptor-associated protein (RAP) and compositions thereof, methods of generating such variants and methods of using such receptor-selective RAP variant compositions for therapeutic purposes. The invention also relates to antibodies that bind to one or a small subset of CR-containing proteins.

Claims

1. A polypeptide comprising an amino acid sequence variant of the mature alpha-2-macroglobulin/low density lipoprotein receptor-related protein-associated protein 1 (RAP) consisting of an amino acid sequence having at least 90% sequence identity to the amino acids 200-323 set out in SEQ ID NO:

94, wherein said amino acid sequence variant of RAP binds to LRP2 with an affinity that is at least 3-fold greater than binding to LRP1, wherein the RAP variant comprises mutations at two or more of positions 249, 251, 256 and 270.

2. The polypeptide of claim 1, wherein said amino acid sequence variant of RAP binds to LRP2 with an affinity that is at least 3-fold greater than binding to LRP1, LRP6, VLDLR and matriptase.

3. The polypeptide of claim 1 wherein said RAP variant lacks amino acids 320-323 of SEQ ID NO:

94.

4. The polypeptide of claim 1 wherein the variant contains at least one mutation at any one of positions 205, 213, 217, 226, 230, 232, 239, 246, 249, 251, 256, 257, 261, 266, 267, 268, 270, 273, 287, 290, 294, 296, 297, 298, 312, or 313 of RAP.

5. The polypeptide of claim 1 wherein the variant comprises a mutation at position 249 of RAP.

6. The polypeptide of claim 1 wherein the variant comprises a mutation at position 251 of RAP.

7. The polypeptide of claim 1 wherein the variant comprises a mutation at position 256 of RAP.

8. The polypeptide of claim 1 wherein the variant comprises a mutation at position 270 of RAP.

9. The polypeptide of claim 4 wherein the variant contains at least one additional mutation within positions 271-319 of RAP.

10. The polypeptide of claim 4 wherein the variant contains at least one additional mutation within positions 205-250 of RAP.

11. The polypeptide according to any one of claim 4, 9 or 10, wherein said mutation is the replacement of an acidic amino acid with a basic amino acid.

12. The polypeptide of claim 11, wherein said acidic amino acid is selected from the group consisting of D and E.

13. A polypeptide of claim 11, wherein said basic amino acid is selected from the group consisting of K and R.

14. A polypeptide according to any one of claim 4, 9 or 10, wherein said mutation is the replacement of a basic amino acid with an acidic amino acid.

15. A polypeptide of claim 14, wherein said basic amino acid is selected from the group consisting of K and R.

16. A polypeptide of claim 14 wherein said acidic amino acid is selected from the group consisting of D and E.

17. A polypeptide according to any one of claim 4, 9 or 10, wherein said mutation is the replacement of an amino acid selected from the group consisting of A, C, D, E, G, I, K, L, M, N, P, Q, R, S, T, and V with an amino acid selected from the group consisting of F, Y, W, and H.

18. The polypeptide of claim 1 that comprises a mutation at three or more of the following positions:

249, 251, 256 or 270.

19. The polypeptide of claim 18 that comprises three or more of the following mutations:

S213T, E217K, H249Y, E251K, K256A, K270E, R205S, L226M, A230V, S232P, E239G, E246G, E251L, E251K, E251T, E251G, E251P, E251N, E251R, K256R, K256V, K256A, K256I, K256P, K256L, I266F, I266T, H257Y, Q261R, A267V, H268R, K270P, K270D, K270N, K270G, K270W, H273Y, R287H, H290Y, H290L, E294V, R296L, T297I, K298R, S312F, G313D.

20. A polypeptide consisting of oligomeric combinations of polypeptides of claim 1 with multivalent binding properties defined by each polypeptide of the combination.

21. A compound comprising the polypeptide according to claim 1, 4 or 18 conjugated to a diagnostic or therapeutic agent.

22. The compound of claim 21, wherein the polypeptide and diagnostic or therapeutic agent are linked through a linker.

23. The compound of claim 22, wherein said linker is a peptide linker.

24. The compound of claim 21, wherein the therapeutic agent is selected from the group consisting of a glial cell-derived neuronal growth factor (GDNF), brain-derived neuronal growth factor (BDNF), neuronal growth factor (NGF), disintegrin and metalloproteinase domain 10 (ADAM10), a chaperone protein for LRP5/6 (MESD), cancer chemotherapeutic agents, protease inhibitors, pro-apoptotic molecules, autoimmune antigens, lysosomal enzymes, nanoparticles, glycoconjugates and nucleic acids.

25. A pharmaceutical composition comprising a compound of claim 1, 4 or 18 in a pharmaceutically acceptable carrier, diluent or excipient.